---
created: 2025-04-13
updated: 2025-04-13T10:53
id: Ep,{S|4gO?
specialty: cardio
specialty_id: 350
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/b&b::05-cardio::04-arrhythmias::06-antiarrhythmic-drugs
  - "source/ak-step1-v11:": 
  - theme/b&b::05-cardio::06-heart-failure::04-acute-heart-failure
  - "source/ak-step1-v11:": 
  - theme/firstaid::05-pharmacology::02-autonomic-drugs::15-phosphodiesterase-inhibitors
  - "source/ak-step1-v11:": 
  - theme/firstaid::05-pharmacology::02-autonomic-drugs::15-phosphodiesterase-inhibitors::pde-3-inhibitors
  - "source/ak-step1-v11:": 
  - theme/firstaid::05-pharmacology::02-autonomic-drugs::15-phosphodiesterase-inhibitors::pde-3-inhibitors::milrinone-inamrinone
  - "source/ak-step1-v11:": 
  - theme/firstaid::07-cardiovascular::05-pharm::11-cardiac-glycosides::milrinone-inamrinone
  - "source/ak-step1-v11:": 
  - source/ome-banner::clinical::01-cardiology::02-heart-failure
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::10-cardiac::07-milrinone
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::06-cardio::milrinone
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::02-cardio-&-renal::fa-cardio
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^expn::uworld
  - source/ak-step1-v11::^other::^fa-updates::fa2018
  - source/ak-step1-v11::^other::^highyield::3-highyield-temporary
  - source/ak-step1-v11::^systems::cardio::pharmacology
  - "source/ak-step2-v11:": 
  - theme/b&b::07-pulmonary::02-critical-care::01-shock"
type: flashcard
---

# Question
Because milrinone causes both systemic arteriolar and venous dilation, it should not be used in severely **hypotensive** patients

---

# Answer
